Piper Sandler analyst Matt O'Brien raised the firm's price target on Tandem Diabetes to $90 from $70 and keeps an Overweight rating on the shares. Tandem reported Q4 results that exceeded domestic expectations, though international was weaker than expected and the company guided to fiscal 2020 revenue growth of ~26%, above the Street, O'Brien tells investors in a research note. The shares will most likely be weighed down by the international "noise" and t:sport commercial delay, says the analyst. However, O'Brien recommends taking advantage of any weakness.